Refractory anti-NMDAR encephalitis successfully treated with bortezomib and associated movements disorders controlled with tramadol: a case report with literature review

Serena Marita Lazzarin, Marco Vabanesi, Giordano Cecchetti, Raffaella Fazio, Giovanna Franca Fanelli, Maria Antonietta Volonté, Angela Genchi, Antonino Giordano, Vittorio Martinelli, Sergio Colombo, Paolo Beccaria, Milena Mucci, Jacopo Peccatori, Massimo Filippi, Fabio Minicucci

Research output: Contribution to journalArticlepeer-review

Abstract

Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis is a potentially fatal autoimmune disease, characterized by autoantibody-mediated neurotransmission impairment in multiple brain locations. The course of this condition often comprises altered mental status, autonomic dysfunctions, refractory seizures and hyperkinetic movement disorders. Available disease-modifying therapies include corticosteroids, i.v. immunoglobulins, plasma exchange, rituximab and cyclophosphamide. In a subgroup of patients not responding to B-cell depletion, bortezomib, a proteasome inhibitor, has shown promising evidence of efficacy. The time course of recovery from acute phase may be very slow (weeks/months), and only few data are available in literature about the concurrent management of encephalitis-associated movement disorders. We report a case of severe anti-NMDAR encephalitis in a 29-year-old woman, not responsive to first- and second-line treatments, with persistent involuntary motor manifestations. Starting three months after symptom onset, four cycles of bortezomib have been administered; subsequently we observed a progressive improvement of neurological status. Meanwhile, motor manifestations were controlled after the administration of tramadol, a non-competitive NMDA receptor antagonist.

Original languageEnglish
Pages (from-to)2462-2468
Number of pages7
JournalJournal of Neurology
Volume267
Issue number8
DOIs
Publication statusPublished - Aug 1 2020

Keywords

  • Anti-NMDAR encephalitis
  • Autoimmune encephalitis
  • Bortezomib
  • EEG
  • Movement disorders

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Fingerprint

Dive into the research topics of 'Refractory anti-NMDAR encephalitis successfully treated with bortezomib and associated movements disorders controlled with tramadol: a case report with literature review'. Together they form a unique fingerprint.

Cite this